BioSpace News Archive

Nucleic acid isolation, or DNA isolation, is a procedure that involves the distillation of a given DNA sample using a number of combined chemical and physical processes.

The hypoxia chamber market has made strides on the back of the growing application of these in cell culture studies.

Global biotechnology leader in animal genetics reports continued strong performance for the six-months period ending December 31, 2020.

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease

Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today issued the following letter from Robert Cohen, Chief Executive Officer, updating Zomedica’s shareholders regarding several key activities and events:

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to provide genomic sequencing to identify new mutations in, and patterns of transmission of SARS-CoV-2, the virus that causes COVID-19.

Following the overwhelming success of last year’s very first Career Connect Day, LifeSciences BC, a non-governmental, non-profit association supporting the life sciences sector of British Columbia and BioTalent Canada, the HR partner of and catalyst for growth in Canada’s bio-economy, are partnering again to bring together the largest life science job fair in B.C., the virtual LifeSciences BC Career Connect Day event

TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses, announced today that it has entered into a research collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine